An Open-label, Multi-Centre Trial Investigating Pharmacokinetics of Degarelix After a Starting Dose of 240 mg (40 mg/mL) Followed by Six Maintenance Doses of 80 mg (20 mg/mL) in Chinese Patients With Prostate Cancer Requiring Androgen Deprivation Therapy
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Ferring Pharmaceuticals
- 18 Apr 2016 Planned End Date changed from 1 Jul 2016 to 1 Oct 2017.
- 18 Apr 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Oct 2016.
- 18 Apr 2016 Status changed from recruiting to active, no longer recruiting.